158 related articles for article (PubMed ID: 22964015)
1. Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study.
Galimberti S; Guerrini F; Salvi F; Petrini I; Gioia D; Messa E; Palumbo GA; Cilloni D; Petrini M; Levis A
J Hematol Oncol; 2012 Sep; 5():53. PubMed ID: 22964015
[TBL] [Abstract][Full Text] [Related]
2. [Mechanisms of arsenic trioxide induced tumor cell apoptosis in myelodysplastic syndrome mice model in vivo].
Lu J; Jin J
Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):782-6. PubMed ID: 17229386
[TBL] [Abstract][Full Text] [Related]
3. NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs).
Kerbauy DM; Lesnikov V; Abbasi N; Seal S; Scott B; Deeg HJ
Blood; 2005 Dec; 106(12):3917-25. PubMed ID: 16105982
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Rep; 2005 Jan; 4(1):59-63. PubMed ID: 15610661
[TBL] [Abstract][Full Text] [Related]
5. [Experimental study of the anti-tumor effect of arsenic trioxide or thalidomide alone and combination of both for treatment of myelodysplastic syndrome model].
Lu J; Jin J; Xu WL
Zhonghua Er Ke Za Zhi; 2006 Mar; 44(3):228-33. PubMed ID: 16624066
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide as a treatment for myelodysplastic syndrome.
Sekeres MA
Curr Hematol Malig Rep; 2006 Mar; 1(1):34-8. PubMed ID: 20425329
[TBL] [Abstract][Full Text] [Related]
7. Curcumin reduces the expression of survivin, leading to enhancement of arsenic trioxide-induced apoptosis in myelodysplastic syndrome and leukemia stem-like cells.
Zeng Y; Weng G; Fan J; Li Z; Wu J; Li Y; Zheng R; Xia P; Guo K
Oncol Rep; 2016 Sep; 36(3):1233-42. PubMed ID: 27430728
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of wt1 expression in leukemia cell lines as part of apoptotic effect in arsenic treatment using two compounds.
Glienke W; Chow KU; Bauer N; Bergmann L
Leuk Lymphoma; 2006 Aug; 47(8):1629-38. PubMed ID: 16966277
[TBL] [Abstract][Full Text] [Related]
9. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes.
List A; Beran M; DiPersio J; Slack J; Vey N; Rosenfeld CS; Greenberg P
Leukemia; 2003 Aug; 17(8):1499-507. PubMed ID: 12886236
[TBL] [Abstract][Full Text] [Related]
10. Alteration in miRNA gene expression pattern in acute promyelocytic leukemia cell induced by arsenic trioxide: a possible mechanism to explain arsenic multi-target action.
Ghaffari SH; Bashash D; Dizaji MZ; Ghavamzadeh A; Alimoghaddam K
Tumour Biol; 2012 Feb; 33(1):157-72. PubMed ID: 22072212
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity.
Wu X; Hu Z; Nizzero S; Zhang G; Ramirez MR; Shi C; Zhou J; Ferrari M; Shen H
J Control Release; 2017 Dec; 268():92-101. PubMed ID: 29042320
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide prevents osteosarcoma growth by inhibition of GLI transcription via DNA damage accumulation.
Nakamura S; Nagano S; Nagao H; Ishidou Y; Yokouchi M; Abematsu M; Yamamoto T; Komiya S; Setoguchi T
PLoS One; 2013; 8(7):e69466. PubMed ID: 23861973
[TBL] [Abstract][Full Text] [Related]
13. High-dose ascorbate and arsenic trioxide selectively kill acute myeloid leukemia and acute promyelocytic leukemia blasts in vitro.
Noguera NI; Pelosi E; Angelini DF; Piredda ML; Guerrera G; Piras E; Battistini L; Massai L; Berardi A; Catalano G; Cicconi L; Castelli G; D'Angiò A; Pasquini L; Graziani G; Fioritoni G; Voso MT; Mastrangelo D; Testa U; Lo-Coco F
Oncotarget; 2017 May; 8(20):32550-32565. PubMed ID: 28427227
[TBL] [Abstract][Full Text] [Related]
14. Decitabine shows synergistic effects with arsenic trioxide against myelodysplastic syndrome cells via endoplasmic reticulum stress-related apoptosis.
Huang L; Liu Z; Jiang H; Li L; Fu R
J Investig Med; 2019 Oct; 67(7):1067-1075. PubMed ID: 30898879
[TBL] [Abstract][Full Text] [Related]
15. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
Welch JS; Klco JM; Gao F; Procknow E; Uy GL; Stockerl-Goldstein KE; Abboud CN; Westervelt P; DiPersio JF; Hassan A; Cashen AF; Vij R
Am J Hematol; 2011 Sep; 86(9):796-800. PubMed ID: 21815182
[No Abstract] [Full Text] [Related]
16. Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo.
Shen L; Zhang G; Lou Z; Xu G; Zhang G
BMC Complement Altern Med; 2017 Feb; 17(1):106. PubMed ID: 28187727
[TBL] [Abstract][Full Text] [Related]
17. Might arsenic trioxide be useful in the treatment of advanced myelodysplastic syndromes?
Donelli A; Chiodino C; Panissidi T; Roncaglia R; Torelli G
Haematologica; 2000 Sep; 85(9):1002-3. PubMed ID: 10980650
[No Abstract] [Full Text] [Related]
18. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.
Bonati A; Rizzoli V; Lunghi P
Curr Pharm Biotechnol; 2006 Dec; 7(6):397-405. PubMed ID: 17168655
[TBL] [Abstract][Full Text] [Related]
20. [Study on the mechanisms of telomerase regulations during apoptosis of the human MDS-RAEB cell line MUTZ-1 cells induced by arsenic trioxide].
Tong HY; Jin J; Xu WL; Qian WB; Lin MF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):615-9. PubMed ID: 16129045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
